Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — LD Micro Main Event 2018
15 slides from Vivani Medical's conference presentation, Dec 5, 2018
Slide 1: Second Sight Medical Products, Inc. at the LD Micro Main Event
8cond Sight Medical Products, Inc. Tith Annual LD Micro Main Event December 5, 2018 SECC@NDSIGHT (NASDAQ; EYES)
Slide 2: Forward Looking Statements
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" create
Slide 3: Two Breakthrough Technologies: Argus II and Orion
Argus® II Retinal Prosthesis Two Breakthrough Technologies Orion® Visual Cortical Prosthesis First and only FDA approved retinal prosthesis 20+ years and ~$200 million invested to develop and commercialize Established technology with 293+ implants Approved for individuals with advanced retinitis pig
Slide 4: Argus II: Effective Treatment for Blindness
Argus® Il: Effective Treatment for Blindness Argus Il is a retinal prosthesis that induces visual perception in individuals with advanced retinitis pigmentosa (RP) SECONDSIGHT : Video Link: https://youtu.be/ezVNMO5GeUE SECOCNDSIGHT
Slide 5: Strategy Driven by Growing Confidence in Orion
trategy D ven by Growing Confidence in Orion® Research Execute Orion clinical and R&D programs as our top priority * Sixsubject U.S. feasibility study at UCLA and Baylor is ongoing + R&D efforts to iterate cortical prosthesis and external components in preparation for pivotal trial * Orion designate
Slide 6: Orion: Breakthrough Device with Potential to Treat Virtually All Forms of Blindness
Orion®: Breakthrough Device with Potential to Treat Virtually All Forms of Blindness The addressable market for Orion is potentially over 70,000 individuals in the U.S.; a multi-billion dollar market opportunity Market outside U.S. expected to be larger Approximately Legally blind due to glaucoma, d
Slide 7: Orion Feasibility Study
our * Conducting a six subject feasibility study at Ronald Reagan UCLA Medical Center and the Baylor College of Medicine + Five subjects implanted and activated in1H 2018 + Recruiting sixth patient at Baylor College of Medicine * Observations from our early testing include the following: « Four pati
Slide 8: Research Technologies to Enhance User Experience
Research Technologies to Enhance User Experience Eye Tracking Depth-Based Decluttering Move the implant field of view Allow users to filter out objects in conjunction with the further than a defined distance movement of the user's eyes Thermal imaging Object & Facial Recognition Infrared ima Ww Rece
Slide 9: Argus II Strategy: Capital Efficiency & Building Strategic Value
Argus® II Strategy: Capital Efficiency & Building Strategic Value 0 create artificial SEC@NDSIGHT
Slide 10: Commercial Experience & Centers of Excellence
‘Commercial Experience & ‘i <G> Centers of Excellence (COE) model and artificial vision rehabilitation =. Centers of Excellence model to build regional artificial vision centers for Argus and Orion + Best practices development and pioneered post-surgical rehabilitation to improve patient satisfactio
Slide 11: Research Feasibility Study to Commercial
RESEARCH FEASIBILITY STUDY — | vi COMMERCIAL pou Somes Argus Il: Comr Eye Trauma/injury Glaucoma Diabetic Retinopathy Optic Nerve Disease Higher electrode count, bilateral implants Enhancements to User Experience 4 SEC@NDSIGHT
Slide 12: Key Drivers of Shareholder Value through 2019
Key Drivers of Shareholder Value through 2019 Orion a . aa Complete Orion feasibility trial and release interim Initiate Orion pg data from first six subjects Pivotal Trial Agreement on pivotal and post-market trial designs Agreement w/ FDA via the FDA's Breakthrough Device Program for Orion Clinica
Slide 13: Select Financial Data
lect Financial Data (USD $ in thousands) | Q3 2018 FY 2017 FY 2016 75 42 Implants 20 (30 in Q4) (7 in Q4) Revenue $2,246 $7,964 $3,985 Gross Profit (Loss) $462 $2,847 $(6,091) Net Loss $(8,522) $(28,516) $(33,179) Non-GAAP Adjusted Net Loss’ $(7,535) $(27,576) $(24,812) 1) Non-GAAP adjusted net loss
Slide 14: Second Sight Investment Highlights
Second Sight Investment Highlights Argus II business focused on capital efficiency and strategic benefit + — ROl and cost structure improvements important when evaluating markets or expansion + Commercial competencies and R&D efforts such as Argus 2s next-gen externals that benefit Orion are priorit
Slide 15: Contacts
Contacts Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 www.secondsight.com Will McGuire President & CEO Direct: 818-833-5040 wmcquire@secondsight.com fail Investor Relations _ Institutional Investor Relations Greg Falesnik Lisa Wilson Manag
Second Sight Medical Products — LD Micro Main Event 2018 on 6ix